Search company, investor...

Alexza Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About Alexza Pharmaceuticals

Alexza Pharmaceuticals develops drugs for acute and intermittent medical conditions. Their Staccato system aerosolizes without thermal degradation, enabling convenient delivery and rapid therapeutic onset of many small molecule drugs. The company has product candidates in clinical trials for migraine headaches, acute panic attacks, acute agitation in schizophrenia and acute pain.

Headquarters Location

2091 Stierlin Court

Mountain View, California, 94043,

United States


Missing: Alexza Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alexza Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alexza Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alexza Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alexza Pharmaceuticals Patents

Alexza Pharmaceuticals has filed 67 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Aerosols
  • Drug delivery devices
patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Drug delivery devices, Routes of administration, Medical equipment, Medical treatments


Application Date


Grant Date



Related Topics

Dosage forms, Drug delivery devices, Routes of administration, Medical equipment, Medical treatments



Latest Alexza Pharmaceuticals News

Acute Repetitive Seizures Market to See Huge Growth by 2028 | Companies Valeant Pharmaceuticals, Alexza Pharmaceuticals, Veriton Pharma Limited, Sanofi, Pfizer Inc.

Feb 2, 2021

| Companies Valeant Pharmaceuticals, Alexza Pharmaceuticals, Veriton Pharma Limited, Sanofi, Pfizer Inc. This Fact.MR study on the Acute Repetitive Seizures Market is a data-driven insight into its key evolution trajectories and scrutiny of the current and emerging avenues in the various segments. The report authors have offered a comprehensive assessment of the various growth dynamics during the historical period. The analysts have made a critical evaluation of the avenues that will shape the contours of the Acute Repetitive Seizures Market during the forecast period 2018 to 2028. The market intelligence report strives to present an all-round insight into the trends and opportunities in the Acute Repetitive Seizures Market . In doing so, the analysts have discussed at length the major aspects such as forces of competition, buyers’ behavior and their bargaining power, changing technological landscape, government regulations and policies. The study is a phenomenal combination of expert analysis, systematic research procedures, and the right information to fulfill the knowledge requirements of the stakeholders and CXOs. The study comprises market intelligence that assists in brightening the prospects of the stakeholders and CXOs, enabling them to explore the pathway toward growth. New business and information system interaction models that are fast rising to prominence due to Covid-19 disruptions are also covered in the study on the global market. To remain ‘ahead’ of your competitors, request for a sample>>> Some of the hard-to-arrive-at insights and projections that make the study unique in approach and objectives for market participants notably include: Which business models are losing their relevance in the post-Covid era? Which countries have made large regulatory changes to attract investments in the industries associated with the Acute Repetitive Seizures Market? Which new technology trends will lead to major strategic overhauls of top companies in the Acute Repetitive Seizures Market? Which are some of the consumer value capture moves made by new entrants to gain a foothold in the market? Which offering will help top players revive their high growth in coming months? Which geographies will be next destination for venture capitalists? What are some of the game-changing strategies being mulled over by prominent industry participants? Acute Repetitive seizure Market: Segmentation Tentatively, Acute Repetitive seizure Market has been segmented on the basis of product type, application, and end user. On the basis of Drug Class, Acute Repetitive seizure Market can be segmented as: Benzodiazepines Oral Hospital pharmacy Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM) EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc. ), Rest of Europe CIS & Russia Some of the important questions covered in this study are as follows: What are the prominent growth factors that will harness growth for the Acute Repetitive Seizures Market during the forecast period 2018 to 2028? Which end-use industry will garner considerable growth for the Acute Repetitive Seizures Market? Which region will emerge as a champion growth-contributor during the assessment period 2018 to 2028? What are the obstacles surrounding the Acute Repetitive Seizures Market? How can Fact.MR Make Difference? In-depth understanding of key industry trends shaping the present growth dynamics Offers value chain analysis and price trend analysis of various offering of competitors Offers data-drive decision to help companies decide strategies that need recalibration Offers insights into areas in research and development that should attract Identifies data outliers before your competitors About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact:

Alexza Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Alexza Pharmaceuticals founded?

    Alexza Pharmaceuticals was founded in 2000.

  • Where is Alexza Pharmaceuticals's headquarters?

    Alexza Pharmaceuticals's headquarters is located at 2091 Stierlin Court, Mountain View.

  • What is Alexza Pharmaceuticals's latest funding round?

    Alexza Pharmaceuticals's latest funding round is Acquired.

  • How much did Alexza Pharmaceuticals raise?

    Alexza Pharmaceuticals raised a total of $109.43M.

  • Who are the investors of Alexza Pharmaceuticals?

    Investors of Alexza Pharmaceuticals include Grupo Ferrer Internacional, EDBI, Presidio Partners, Zesiger Capital Group, New Enterprise Associates and 19 more.

  • Who are Alexza Pharmaceuticals's competitors?

    Competitors of Alexza Pharmaceuticals include Zosano Pharma, CoLucid Pharmaceuticals, BioCardia, Pozen, Auspex Pharmaceuticals, Ultragenyx Pharmaceutical, Agios Pharmaceuticals, NovoLogix, CNSBio, ThyroChek and 13 more.

Compare Alexza Pharmaceuticals to Competitors


SoluBest is a clinical stage pharmaceutical company developing nanoformulations of existing therapeutic medicines in several fields. Solubest uses its advanced polymer formulations to prepare nano-particles of drugs with delivery or compliance insufficiencies. SoluBest's pipeline of existing off-patent drugs are being re-formulated for:nn * its own product developmentn * co-development partners

Symphony Allegro

Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder


Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.


Euroflow develop technologies, products and services for the development and production of new therapeutic drugs based on chromatographic techniques, with the aim of bringing new products to market quickly.

Emagin Therapeutics

Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.